✨ Onyx Summary Geron Corporation granted inducement equity awards to 16 new hires totaling 966,000 shares—644,000 stock options at a $1.27 exercise price and 322,000 RSUs—under Nasdaq Listing Rule 5635(c)(4), with grants dated September 17, 2025 and four-year vesting schedules. The move aligns
✨ Onyx Summary MassBio, SCbio, Venture Carolina, VentureSouth, and the South Carolina Department of Commerce launched the Palmetto Beacon Venture Fellowship, a program designed to educate and empower the next generation of biotech investors through immersive sessions in Charleston, John’s Island, and Boston. By bridging ecosystems from the Southeast to
✨ Onyx Summary Lexicon Pharmaceuticals presented new Phase 2b PROGRESS study data for its investigational AAK1 inhibitor, pilavapadin, at the NEUROdiab and EASD 2025 meetings, showing that the 10 mg once-daily dose achieved a statistically and clinically meaningful reduction in diabetic peripheral neuropathic pain while maintaining strong tolerability. The findings strengthen
✨ Onyx Summary Cellares announced multiple technology partnerships to advance Cell Q™, the first fully automated, modular quality control platform designed to handle the commercial-scale throughput required for cell therapy manufacturing. By integrating best-in-class systems from partners like Tecan, Cytek, and Advanced Instruments, Cell Q sets a new standard for compliance,
✨ Onyx Summary Piramal Pharma Solutions announced the acquisition of a Korsch XM-12 bilayer tablet press for its Morpeth, UK facility, enhancing its capabilities in oral solid and hormonal drug product development and manufacturing. The investment strengthens precision, flexibility, and containment in tablet production, supporting Piramal’s commitment to advanced drug
✨ Onyx Summary SpyGlass Pharma appointed Anand Sundaram as Vice President, Head of Commercial, to lead launch strategy and build its commercial organization ahead of two planned Phase III trials for its sustained drug delivery platform. Sundaram brings extensive ophthalmic commercialization experience from Opthea, Iveric Bio, Novartis, and Genentech, strengthening SpyGlass’
✨ Onyx Summary MassBio will host the 2025 Eisai R&D Day on October 20 at Eisai’s G2D2 Center in Cambridge, featuring panel discussions, poster sessions, and networking to showcase Eisai’s R&D priorities in neuroscience, oncology, and global health. By fostering direct engagement between Eisai and
✨ Onyx Summary Avidity Biosciences closed a $690 million public offering of 17.25 million shares at $40 each, including the full exercise of underwriters’ option to purchase additional shares. The proceeds will support late-stage clinical development of its Antibody Oligonucleotide Conjugates (AOCs), preparation for multiple product launches, expansion of commercial
✨ Onyx Summary Perspective Therapeutics has dosed the first patient in a new Phase 1/2a cohort evaluating [212Pb]VMT01, its targeted alpha-particle therapy, in combination with Bristol Myers Squibb’s nivolumab (Opdivo®) for patients with metastatic melanoma. The expansion to a higher 3.0 mCi dose and combination arm marks
✨ Onyx Summary Ocugen has licensed exclusive rights to its investigational gene therapy OCU400 for retinitis pigmentosa to Kwangdong Pharmaceutical in South Korea, with upfront and milestone payments of up to $7.5 million, sales milestones tied to $180 million in projected 10-year sales, and a 25% royalty on net sales.
✨ Onyx Summary Guardant Health announced the appointment of former U.S. Health and Human Services Secretary Alex M. Azar II to its board of directors, bringing extensive leadership experience from both government and the private sector. His addition underscores Guardant’s ambition to pair policy expertise with scientific innovation, strengthening
✨ Onyx Summary Kyverna Therapeutics will present interim Phase 2 data from the KYSA-6 study of its CD19 CAR T-cell therapy KYV-101 in generalized myasthenia gravis at the 2025 AANEM Annual Meeting. The results, part of a registrational Phase 2/3 study, will include efficacy and safety data for six patients
✨ Onyx Summary Belite Bio completed the last subject visit in its global Phase 3 DRAGON trial of tinlarebant for Stargardt disease type 1, which enrolled 104 adolescents across 11 jurisdictions (94 completed); the primary endpoint is the growth rate of atrophic lesions with safety/tolerability assessed. Top-line data are expected
✨ Onyx Summary Lexicon Pharmaceuticals will present clinical data for its investigational AAK1 inhibitor, pilavapadin, at three meetings: NeuroDiab (Sept. 13, 2025, Bucharest), EASD (Sept. 17, 2025, Vienna), and Arrowhead’s Pain Therapeutics Summit (Oct. 13–14, 2025, San Diego), with sessions led by Dr. Rodica Pop-Busui and Dr. Suma Gopinathan.
✨ Onyx Summary Avidity Biosciences priced an upsized public offering of 15 million shares at $40 each, expected to raise $600 million before expenses, with underwriters granted a 30-day option to purchase up to 2.25 million additional shares. Proceeds will be used to advance its three late-stage RNA therapeutic programs,
✨ Onyx Summary Guardant Health announced a strategic agreement with LabFlorida/SunDx Labs to make its FDA-approved Shield™ blood test for colorectal cancer screening available to residents of senior living communities across Florida. By extending Shield to this high-risk, underserved population, the partnership could transform preventive care in aging communities—removing
![Perspective Therapeutics Progresses Dose Finding for [212Pb]VMT01 in Combination with Nivolumab in its Ongoing Phase 1/2a Study of MC1R-Positive Metastatic Melanoma](/content/images/size/w1304/format/webp/2025/10/Perspective-1.png)
